Express Scripts Margins Could Face Downward Pressure From Less Prescription Growth

0 Comments 5 view(s)

Argus’ David Toung reiterated Express Scripts Holding Company (NASDAQ: ESRX)’s Hold rating after forecasting slow prescription growth for the company.

Latest Ratings for ESRX

Date Firm Action From To
Jul 2016 Barclays Maintains Overweight
Jun 2016 Morgan Stanley Downgrades Underweight
Jun 2016 Bernstein Initiates Coverage on Underperform

View More Analyst Ratings for ESRX

View the Latest Analyst Ratings

Powered by WPeMatico